MENU
 Pharmaceutical Manufacturers Association of Japan
  • Contact Us
  • Access
  • English
  • About us

    About Pharmaceutical Manufacturers Association Top

    • Top Message
    • Outline of the Pharmaceutical Manufacturers Association of Japan
    • Policies and Activities
    • Voluntary Standards
    • Industry Vision and Proposals
    • Organization
    • Member Companies
  • About Pharmaceuticals

    About Pharmaceuticals Top

    • General Drug Guide
    • Clinical Trials Information
    • Together with Patients
  • Information from the Committee

    Information from the Committee Top

    • Code Compliance Promotion Committee
    • Industry Policy Committee
    • Distribution Appropriateness Committee
    • Drug Evaluation Committee
    • Quality Committee
    • Biopharmaceutical Committee
    • Regulatory Affairs Committee
    • Intellectual Property Committee
    • Research and Development Committee
    • International Committee
    • Public Relations Committee
    • Patient Organization Collaboration Promotion Committee
    • ICH Project
    • APAC Project
    • Pharmaceutical Counseling and Response Review Committee
    • Environmental Issues Review Committee
  • Newsletter
  • News Room

    Newsroom Top

    • News Release
    • Pharmaceutical Association of Japan Newsletter
    • Updates
    • Publications
    • Events
    • Video Content and Advertisements
  • Pharmaceutical Industry Policy Institute
Close
 Pharmaceutical Manufacturers Association of Japan

Return to Site Top

  • Patients and the general public (About Pharmaceuticals)
    For Patients and the Public (About Pharmaceuticals) Top
    • General Drug Guide
    • Clinical Trials Information
    • Together with Patients
  • Information from the Committee
    Information from the Committee Top
    • Code Compliance Promotion Committee
    • Industry Policy Committee
    • Distribution Appropriateness Committee
    • Drug Evaluation Committee
    • Quality Committee
    • Biopharmaceutical Committee
    • Regulatory Affairs Committee
    • Intellectual Property Committee
    • Research and Development Committee
    • International Committee
    • Public Relations Committee
    • Patient Organization Collaboration Promotion Committee
    • ICH Project
    • APAC Project
    • Pharmaceutical Counseling and Response Review Committee
    • Environmental Issues Review Committee
  • About us
    About Pharmaceutical Manufacturers Association Top
    • Top Message
    • Outline of the Pharmaceutical Manufacturers Association of Japan
    • Policies and Activities
    • Voluntary Standards
    • Industry Vision and Proposals
    • Organization
    • Member Companies
  • Policies and Activities
    Policies and Activities Top
    • Business Policy, Business Plan, Implementation Plan
    • Committee Activities
    • Convention on Biological Diversity
  • Voluntary Standards
    Voluntary Standards Top
    • Charter of Conduct
    • Pharmaceutical Association Code of Practice
    • Transparency Guidelines for Relationships between Corporate Activities and Medical Institutions
    • Transparency Guidelines for Relationships between Corporate Activities and Patient Groups
    • Guidelines for the Preparation of Product Information Summaries for Ethical Drugs (Abbreviated name: Preparation Guidelines)
    • Clinical Research
    • Basic Philosophy and Action Guidelines on Biodiversity
    • Guidelines for Appropriate Competition in the Meetings of the Japan Pharmaceutical Manufacturers Association (JPMA)
    • Guidelines for the Promotion of Pharmaceutical Industry
  • News Room
    Newsroom Top
    • News Release
    • Pharmaceutical Association of Japan Newsletter
    • Updates
    • Publications
    • Events
    • Video Content and Advertisements
  • Pharmaceutical Industry Policy Institute Page will open in a new window.
  • Social Media Policy
  • Website Terms of Use
  • Industry Vision, Policy Recommendations
    Industry Vision and Policy Recommendations Top
    • Toward the realization of the Pharmaceutical Manufacturers Association of Japan Industry Vision 2035
    • Chairman's Press Conference, Speeches and Comments
    • Back Number: Vision, Proposals
  • Contact Us
  • Access
  • English
  • Top
  • Information from the Committee
  • Drug Evaluation Committee
  • Drug Evaluation Committee Symposium
  • Materials for "Workshop for Practitioners on Electronic Data Submission at the Time of Application" in FY2022

Drug Evaluation Committee Materials for "Workshop for Practitioners on Electronic Data Submission at the Time of Application" in FY2022

Mar 02, 2023

  • 00_Program (170KB)
  • 01_Examination of the relationship between explanatory materials (Form A) and data guides for electronic data at the time of application (1.84MB)
  • 02. Proposal of Best Practice for electronic data submission using data prepared by other companies (3.94MB)
  • 03_Electronic Data Submission for PPK Analysis: What You Need to Know (3.84MB)
  • 04_Questionnaire results on the impact of eCTD v4.0 on the electronic data submission process (886KB)
  • 05. Points that CDISC staff of CROs should pay attention to when complying with eCTD V4.0 (862KB)
  • 06_Current Status and Points to Consider Concerning Electronic Data Submission of Applications (840KB)
  • 07_Update on eCTD v4 and Gateway (1.96MB)
  • 08_Introduction of internal process study for electronic data submission of applications with eCTD Ver. 4.0 (1.31MB)
  • 09_Best Practices for Early Transition to Online Submission as Communicated by Regulatory Affairs Operations Involved in Gateway Submission from the Early Days (1.38MB)

Return to Drug Evaluation Committee Symposium Top

Share this page

  • Tweet
  • Share this page

TOP

Site Search

  • Top
  • Information from the Committee
  • Drug Evaluation Committee
  • Drug Evaluation Committee Symposium
  • Materials for "Workshop for Practitioners on Electronic Data Submission at the Time of Application" in FY2022
  • Pharmaceutical Association of Japan PR and Communication Activities
  • Pharmaceutical Research Institute
  • Non-Financial Information Disclosure by Member Companies
  • STOP AMR
  • What is the Pharmaceutical Manufacturers Association of Japan (PMAJ)?
  • Policies and Activities
  • Voluntary Standards
  • Global Health
  • News Room
  • For Patients and the Public (About Pharmaceuticals)
  • Clinical Trials Information
  • Information from the Committee
  • English Page will open in a new window.
  •  x
  •  facebook
  •  youtube
  • Site Map
  • Contact Us
  • Website Terms of Use
  • Privacy Policy
  • Social Media Policy
  • Linking to Our Site
  • Accessibility Policy
  • PRAISE-NET Login

© Japan Pharmaceutical Manufacturers
Association(JPMA).All rights reserved.